Sign In
Buy MRK
$120.78
+1.69 (+1.41%)
At Close: Jun 11, 2026
Merck Sales Rise on Continued Keytruda Growth
06:51am, Thursday, 30'th Apr 2026
Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow.
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
06:32am, Thursday, 30'th Apr 2026
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales guida
Merck posts quarterly loss due to Cidara charge, sales rise 5%
06:31am, Thursday, 30'th Apr 2026
Merck & Co on Thursday reported a loss for the first quarter as an acquisition-related charge offset a 5% increase in product sales driven by cancer and respiratory drugs.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:56am, Wednesday, 29'th Apr 2026
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
07:21am, Wednesday, 29'th Apr 2026
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:57am, Tuesday, 28'th Apr 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional ba
Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
01:15pm, Monday, 27'th Apr 2026
LLY, MRK, ABBV, BMY and BIIB are set to report this week as recent beats and key drug demand set up a pivotal Q1 earnings test for pharma giants.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 27'th Apr 2026
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
11:02am, Monday, 27'th Apr 2026
Merck MRK is set to report its first-quarter 2026 earnings on April 30, before market open. The Zacks Consensus Estimate for first-quarter top line is pegged at $15.90 billion, while the same for th
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS
10:16am, Monday, 27'th Apr 2026
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarte
Top insights from the latest market news from Monday, April 27, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Merck: Bullish Setup Into Q1 Earnings
08:39am, Monday, 27'th Apr 2026
Merck & Co., Inc. will publish its first-quarter figures at the end of April. I again expect strong performance from Keytruda and Winrevair. However, in the report itself, I believe the defining momen
D.A. Davidson & CO. Raises Stake in Merck & Co., Inc. $MRK
07:58am, Monday, 27'th Apr 2026
D.A. Davidson and CO. increased its stake in Merck and Co., Inc. (NYSE: MRK) by 4.4% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 576,959 shares of the c
